When tested against BACE1 (β-site Amyloid precursor protein Cleaving Enzyme type 1), an enzyme implicated in Alzheimer’s disease, compound 40 was about 12- to 30-fold less active as an BACE1 inhibitor compared to cathepsins D and E [104]. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.